MENU
Showcases Stock ranks Forex

Cue Biopharma Inc (CUE)
1.89  0.05 (2.72%) 03-28 16:00
Open: 1.86 Pre. Close: 1.84
High: 1.94 Low: 1.85
Volume: 187,949 Market Cap: 85(M)
Stock Technical Analysis
Overall:     
Target: Six months: 2.50
One year: 2.77
Support: Support1: 1.76
Support2: 1.46
Resistance: Resistance1: 2.14
Resistance2: 2.37
Pivot: 1.93
Moving Averages: MA(5): 1.87
MA(20): 1.95
MA(100): 2.46
MA(250): 2.98
MACD: MACD(12,26): -0.10
Signal(12,26,9): -0.11
%K %D: %K(14,3): 19.88
%D(3): 19.33
RSI: RSI(14): 43.49
52-Week: High: 5.12
Low: 1.7
Change(%): -46.6
Average Vol(K): 3-Month: 262
10-Days: 212
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 1.874 - 1.887 1.887 - 1.898
Low: 1.73 - 1.746 1.746 - 1.759
Close: 1.816 - 1.84 1.84 - 1.863
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ CUE ] has closed above bottom band by 38.4%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Stock chart
Stock News
Thu, 14 Mar 2024
Cue Biopharma (NASDAQ:CUE) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World

Wed, 13 Mar 2024
Jefferies starts Cue at buy, cites partnering potential (NASDAQ:CUE) - Seeking Alpha

Wed, 13 Mar 2024
Cue Biopharma (NASDAQ:CUE) Coverage Initiated at Jefferies Financial Group - MarketBeat

Wed, 13 Mar 2024
Healthcare Stocks Moving Up and Down Wednesday: HRTX, ELOX, CRDF, CUE, TNON, TSVT, WORX, ADCT - InvestorsObserver

Wed, 13 Mar 2024
Jefferies starts Cue Biopharma stock at Buy on IL-2 platform promise By Investing.com - Investing.com

Thu, 29 Feb 2024
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers ... - Yahoo Finance

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Underperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 45.12
% Held by Insiders 39460000.00
% Held by Institutions 4.73
Shares Short (K) 3600
Shares Short Prior Month (K)
Stock Financials
EPS -52560000.000
Book Value (p.s.)
Profit Margin
Operating Margin -543.76
Return on Assets (ttm) -45.8
Return on Equity (ttm) -111.1
Qtrly Rev. Growth 2.0
Gross Profit (p.s.) 484.412
Sales Per Share 1872549.000
EBITDA (p.s.)
Qtrly Earnings Growth -1.20
Operating Cash Flow (M)
Levered Free Cash Flow (M) -39.52
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow 4.06
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 3970000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android